Compile Data Set for Download or QSAR
Report error Found 26 Enz. Inhib. hit(s) with all data for entry = 10230
TargetGlutamate receptor ionotropic, NMDA 2A(Human)
Sage Therapeutics

US Patent
LigandPNGBDBM521725(US11149056, Compound U6472)
Affinity DataEC50:  13nMAssay Description:Cells are transferred as suspension in serum-free medium to the QPatch HTX system and kept in the cell storage tank/stirrer during experiments. All s...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/13/2022
Entry Details
US Patent

TargetGlutamate receptor ionotropic, NMDA 2B(Human)
Sage Therapeutics

US Patent
LigandPNGBDBM521725(US11149056, Compound U6472)
Affinity DataEC50:  22nMAssay Description:Cells are transferred as suspension in serum-free medium to the QPatch HTX system and kept in the cell storage tank/stirrer during experiments. All s...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/13/2022
Entry Details
US Patent

TargetGlutamate receptor ionotropic, NMDA 2B(Human)
Sage Therapeutics

US Patent
LigandPNGBDBM521722(US11149056, Compound U6450)
Affinity DataEC50:  66nMAssay Description:Cells are transferred as suspension in serum-free medium to the QPatch HTX system and kept in the cell storage tank/stirrer during experiments. All s...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/13/2022
Entry Details
US Patent

TargetGlutamate receptor ionotropic, NMDA 2B(Human)
Sage Therapeutics

US Patent
LigandPNGBDBM521717(US11149056, Compound U6408)
Affinity DataEC50:  132nMAssay Description:Cells are transferred as suspension in serum-free medium to the QPatch HTX system and kept in the cell storage tank/stirrer during experiments. All s...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/13/2022
Entry Details
US Patent

TargetGlutamate receptor ionotropic, NMDA 2B(Human)
Sage Therapeutics

US Patent
LigandPNGBDBM521724(US11149056, Compound U6478)
Affinity DataEC50:  160nMAssay Description:Cells are transferred as suspension in serum-free medium to the QPatch HTX system and kept in the cell storage tank/stirrer during experiments. All s...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/13/2022
Entry Details
US Patent

TargetGlutamate receptor ionotropic, NMDA 2A(Human)
Sage Therapeutics

US Patent
LigandPNGBDBM521724(US11149056, Compound U6478)
Affinity DataEC50:  191nMAssay Description:Cells are transferred as suspension in serum-free medium to the QPatch HTX system and kept in the cell storage tank/stirrer during experiments. All s...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/13/2022
Entry Details
US Patent

TargetGlutamate receptor ionotropic, NMDA 2A(Human)
Sage Therapeutics

US Patent
LigandPNGBDBM521717(US11149056, Compound U6408)
Affinity DataEC50:  230nMAssay Description:Cells are transferred as suspension in serum-free medium to the QPatch HTX system and kept in the cell storage tank/stirrer during experiments. All s...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/13/2022
Entry Details
US Patent

TargetGlutamate receptor ionotropic, NMDA 2B(Human)
Sage Therapeutics

US Patent
LigandPNGBDBM521715(US11149056, Compound U6429)
Affinity DataEC50:  667nMAssay Description:Cells are transferred as suspension in serum-free medium to the QPatch HTX system and kept in the cell storage tank/stirrer during experiments. All s...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/13/2022
Entry Details
US Patent

TargetGlutamate receptor ionotropic, NMDA 2B(Human)
Sage Therapeutics

US Patent
LigandPNGBDBM521723(US11149056, Compound U6477)
Affinity DataEC50:  698nMAssay Description:Cells are transferred as suspension in serum-free medium to the QPatch HTX system and kept in the cell storage tank/stirrer during experiments. All s...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/13/2022
Entry Details
US Patent

TargetGlutamate receptor ionotropic, NMDA 2A(Human)
Sage Therapeutics

US Patent
LigandPNGBDBM521722(US11149056, Compound U6450)
Affinity DataEC50:  710nMAssay Description:Cells are transferred as suspension in serum-free medium to the QPatch HTX system and kept in the cell storage tank/stirrer during experiments. All s...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/13/2022
Entry Details
US Patent

TargetGlutamate receptor ionotropic, NMDA 2B(Human)
Sage Therapeutics

US Patent
LigandPNGBDBM521720(US11149056, Compound U6437)
Affinity DataEC50:  741nMAssay Description:Cells are transferred as suspension in serum-free medium to the QPatch HTX system and kept in the cell storage tank/stirrer during experiments. All s...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/13/2022
Entry Details
US Patent

TargetGlutamate receptor ionotropic, NMDA 2A(Human)
Sage Therapeutics

US Patent
LigandPNGBDBM521723(US11149056, Compound U6477)
Affinity DataEC50:  747nMAssay Description:Cells are transferred as suspension in serum-free medium to the QPatch HTX system and kept in the cell storage tank/stirrer during experiments. All s...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/13/2022
Entry Details
US Patent

TargetGlutamate receptor ionotropic, NMDA 2B(Human)
Sage Therapeutics

US Patent
LigandPNGBDBM521716(US11149056, Compound U6479)
Affinity DataEC50:  1.43E+3nMAssay Description:Cells are transferred as suspension in serum-free medium to the QPatch HTX system and kept in the cell storage tank/stirrer during experiments. All s...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/13/2022
Entry Details
US Patent

TargetGlutamate receptor ionotropic, NMDA 2A(Human)
Sage Therapeutics

US Patent
LigandPNGBDBM521720(US11149056, Compound U6437)
Affinity DataEC50:  1.63E+3nMAssay Description:Cells are transferred as suspension in serum-free medium to the QPatch HTX system and kept in the cell storage tank/stirrer during experiments. All s...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/13/2022
Entry Details
US Patent

TargetGlutamate receptor ionotropic, NMDA 2A(Human)
Sage Therapeutics

US Patent
LigandPNGBDBM521726(US11149056, Compound U6473)
Affinity DataEC50: >1.00E+4nMAssay Description:Cells are transferred as suspension in serum-free medium to the QPatch HTX system and kept in the cell storage tank/stirrer during experiments. All s...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/13/2022
Entry Details
US Patent

TargetGlutamate receptor ionotropic, NMDA 2A(Human)
Sage Therapeutics

US Patent
LigandPNGBDBM521718(US11149056, Compound U6409)
Affinity DataEC50: >1.00E+4nMAssay Description:Cells are transferred as suspension in serum-free medium to the QPatch HTX system and kept in the cell storage tank/stirrer during experiments. All s...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/13/2022
Entry Details
US Patent

TargetGlutamate receptor ionotropic, NMDA 2B(Human)
Sage Therapeutics

US Patent
LigandPNGBDBM521726(US11149056, Compound U6473)
Affinity DataEC50: >1.00E+4nMAssay Description:Cells are transferred as suspension in serum-free medium to the QPatch HTX system and kept in the cell storage tank/stirrer during experiments. All s...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/13/2022
Entry Details
US Patent

TargetGlutamate receptor ionotropic, NMDA 2B(Human)
Sage Therapeutics

US Patent
LigandPNGBDBM521718(US11149056, Compound U6409)
Affinity DataEC50: >1.00E+4nMAssay Description:Cells are transferred as suspension in serum-free medium to the QPatch HTX system and kept in the cell storage tank/stirrer during experiments. All s...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/13/2022
Entry Details
US Patent

TargetGlutamate receptor ionotropic, NMDA 2A(Human)
Sage Therapeutics

US Patent
LigandPNGBDBM521719(US11149056, Compound U6410)
Affinity DataEC50: >1.00E+4nMAssay Description:Cells are transferred as suspension in serum-free medium to the QPatch HTX system and kept in the cell storage tank/stirrer during experiments. All s...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/13/2022
Entry Details
US Patent

TargetGlutamate receptor ionotropic, NMDA 2B(Human)
Sage Therapeutics

US Patent
LigandPNGBDBM521719(US11149056, Compound U6410)
Affinity DataEC50: >1.00E+4nMAssay Description:Cells are transferred as suspension in serum-free medium to the QPatch HTX system and kept in the cell storage tank/stirrer during experiments. All s...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/13/2022
Entry Details
US Patent

TargetGlutamate receptor ionotropic, NMDA 2A(Human)
Sage Therapeutics

US Patent
LigandPNGBDBM521721(US11149056, Compound U6438)
Affinity DataEC50: >1.00E+4nMAssay Description:Cells are transferred as suspension in serum-free medium to the QPatch HTX system and kept in the cell storage tank/stirrer during experiments. All s...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/13/2022
Entry Details
US Patent

TargetGlutamate receptor ionotropic, NMDA 2B(Human)
Sage Therapeutics

US Patent
LigandPNGBDBM521721(US11149056, Compound U6438)
Affinity DataEC50: >1.00E+4nMAssay Description:Cells are transferred as suspension in serum-free medium to the QPatch HTX system and kept in the cell storage tank/stirrer during experiments. All s...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/13/2022
Entry Details
US Patent

TargetGlutamate receptor ionotropic, NMDA 2A(Human)
Sage Therapeutics

US Patent
LigandPNGBDBM521714(US11149056, Compound U6461)
Affinity DataEC50: >1.00E+4nMAssay Description:Cells are transferred as suspension in serum-free medium to the QPatch HTX system and kept in the cell storage tank/stirrer during experiments. All s...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/13/2022
Entry Details
US Patent

TargetGlutamate receptor ionotropic, NMDA 2B(Human)
Sage Therapeutics

US Patent
LigandPNGBDBM521714(US11149056, Compound U6461)
Affinity DataEC50: >1.00E+4nMAssay Description:Cells are transferred as suspension in serum-free medium to the QPatch HTX system and kept in the cell storage tank/stirrer during experiments. All s...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/13/2022
Entry Details
US Patent

TargetGlutamate receptor ionotropic, NMDA 2A(Human)
Sage Therapeutics

US Patent
LigandPNGBDBM521715(US11149056, Compound U6429)
Affinity DataEC50: >1.00E+4nMAssay Description:Cells are transferred as suspension in serum-free medium to the QPatch HTX system and kept in the cell storage tank/stirrer during experiments. All s...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/13/2022
Entry Details
US Patent

TargetGlutamate receptor ionotropic, NMDA 2A(Human)
Sage Therapeutics

US Patent
LigandPNGBDBM521716(US11149056, Compound U6479)
Affinity DataEC50: >1.00E+4nMAssay Description:Cells are transferred as suspension in serum-free medium to the QPatch HTX system and kept in the cell storage tank/stirrer during experiments. All s...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/13/2022
Entry Details
US Patent